CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
SARS-CoV-2 mRNA vaccination elicits robust antibody responses in children
Authors
Galit Alter
Alejandro B. Balazs
+16 more
Yannic C. Bartsch
Brittany P. Boribong
Madeleine D. Burns
Jameson P. Davis
Andrea G. Edlow
Eva J. Farkas
Alessio Fasano
David Goldblatt
Marina Johnson
Jaewon Kang
Paulina Kaplonek
Evan C. Lam
Wayne G. Shreffler
Kerri J. St. Denis
Lael M. Yonker
Dace Zavadska
Publication date
26 July 2022
Publisher
'American Association for the Advancement of Science (AAAS)'
Doi
Cite
View
on
PubMed
Abstract
Publisher Copyright: Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY)Although children have been largely spared from coronavirus disease 2019 (COVID-19), the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) with increased transmissibility, combined with fluctuating mask mandates and school reopenings, has led to increased infections and disease among children. Thus, there is an urgent need to roll out COVID-19 vaccines to children of all ages. However, whether children respond equivalently to adults to mRNA vaccines and whether dosing will elicit optimal immunity remain unclear. Here, we aimed to deeply profile the vaccine-induced humoral immune response in 6- to 11-year-old children receiving either a pediatric (50 μg) or adult (100 μg) dose of the mRNA-1273 vaccine and to compare these responses to vaccinated adults, infected children, and children who experienced multisystem inflammatory syndrome in children (MIS-C). Children elicited an IgG-dominant vaccine-induced immune response, surpassing adults at a matched 100-μg dose but more variable immunity at a 50-μg dose. Irrespective of titer, children generated antibodies with enhanced Fc receptor binding capacity. Moreover, like adults, children generated cross-VOC humoral immunity, marked by a decline of omicron-specific receptor binding domain, but robustly preserved omicron spike protein binding. Fc receptor binding capabilities were also preserved in a dose-dependent manner. These data indicate that both the 50- and 100-μg doses of mRNA vaccination in children elicit robust cross-VOC antibody responses and that 100-μg doses in children result in highly preserved omicron-specific functional humoral immunity.publishersversionPeer reviewe
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
UCL Discovery
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:eprints.ucl.ac.uk.OAI2:101...
Last time updated on 23/09/2022
Riga Stradins university
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:dspace.rsu.lv:123456789/10...
Last time updated on 12/01/2023
PubMed Central
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pubmedcentral.nih.gov:9348...
Last time updated on 28/09/2022